Short answer
Arcellx, Inc. (ACLX) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $5M (down 81.0% year over year) with net income of −$56M.
Q3 2025 key financials · XBRL
- Revenue
- $5M
- −81.0% YoY · −34.5% QoQ
- Net income
- −$56M
- −115.6% YoY · −5.7% QoQ
- Operating margin
- -1248.3%
- EPS (diluted)
- −$1.00
- −108.3% YoY · −7.5% QoQ
Source: XBRL data from the Arcellx, Inc. (ACLX) Q3 2025 10-Q on SEC EDGAR. USD.
Arcellx, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No changes in cash position, operating cash flow, or capital deployment mentioned
- No management commentary on near-term outlook or updated guidance included
Risk Factors
- New FDA clinical hold risk on anito-cel triggered by previous partial hold requires costly and time-consuming mitigation measures
- Net loss $170.8M for nine months ended Sept 30, 2025 vs $60.3M prior year, reflecting increased R&D and operational costs
- FDA's 15-year post-treatment follow-up requirement for gene therapies introduces long-term regulatory compliance burden
- Competitive risk heightened by reliance on successful development of three ARC-SparX candidates ACLX-001, ACLX-002, ACLX-004 in upcoming trials
- Liquidity risk: existing cash sufficient for 12 months, but accelerated capital consumption may necessitate dilutive financing or unfavorable collaborations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.